175 related articles for article (PubMed ID: 34105966)
21. Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.
Wang ZH; Li DD; Chen WL; You QD; Guo XK
Bioorg Med Chem; 2018 Jan; 26(2):356-365. PubMed ID: 29254892
[TBL] [Abstract][Full Text] [Related]
22. Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.
Borkin D; Klossowski S; Pollock J; Miao H; Linhares BM; Kempinska K; Jin Z; Purohit T; Wen B; He M; Sun D; Cierpicki T; Grembecka J
J Med Chem; 2018 Jun; 61(11):4832-4850. PubMed ID: 29738674
[TBL] [Abstract][Full Text] [Related]
23. WDR5 interacts with mixed lineage leukemia (MLL) protein via the histone H3-binding pocket.
Song JJ; Kingston RE
J Biol Chem; 2008 Dec; 283(50):35258-64. PubMed ID: 18840606
[TBL] [Abstract][Full Text] [Related]
24. Targeting human SET1/MLL family of proteins.
Vedadi M; Blazer L; Eram MS; Barsyte-Lovejoy D; Arrowsmith CH; Hajian T
Protein Sci; 2017 Apr; 26(4):662-676. PubMed ID: 28160335
[TBL] [Abstract][Full Text] [Related]
25. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
[TBL] [Abstract][Full Text] [Related]
26. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of benzylpiperidine inhibitors targeting the menin-MLL1 interface.
Ren J; Xu W; Tang L; Su M; Chen D; Chen YL; Zang Y; Li J; Shen J; Zhou Y; Xiong B
Bioorg Med Chem Lett; 2016 Sep; 26(18):4472-4476. PubMed ID: 27528435
[TBL] [Abstract][Full Text] [Related]
28. Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide.
Patel A; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32158-61. PubMed ID: 18829459
[TBL] [Abstract][Full Text] [Related]
29. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.
Yu X; Li D; Kottur J; Shen Y; Kim HS; Park KS; Tsai YH; Gong W; Wang J; Suzuki K; Parker J; Herring L; Kaniskan HÜ; Cai L; Jain R; Liu J; Aggarwal AK; Wang GG; Jin J
Sci Transl Med; 2021 Sep; 13(613):eabj1578. PubMed ID: 34586829
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Novel, Potent, and Selective Small-Molecule Menin-Mixed Lineage Leukemia Interaction Inhibitors through Attempting Introduction of Hydrophilic Groups.
Lei H; Zhang SQ; Bai H; Zhao HY; Sun J; Chuai H; Xin M
J Med Chem; 2022 Oct; 65(19):13413-13435. PubMed ID: 36173787
[TBL] [Abstract][Full Text] [Related]
32. A conserved arginine-containing motif crucial for the assembly and enzymatic activity of the mixed lineage leukemia protein-1 core complex.
Patel A; Vought VE; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32162-75. PubMed ID: 18829457
[TBL] [Abstract][Full Text] [Related]
33. PHF20L1 antagonizes SOX2 proteolysis triggered by the MLL1/WDR5 complexes.
Wang Q; Yu M; Ma Y; Zhang X; Zhang H; Li S; Lan R; Lu F
Lab Invest; 2018 Dec; 98(12):1627-1641. PubMed ID: 30089852
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting MLL1-WDR5 interaction ameliorates neuropathic allodynia by attenuating histone H3 lysine 4 trimethylation-dependent spinal mGluR5 transcription.
Lin TB; Lai CY; Hsieh MC; Ho YC; Wang HH; Yang PS; Cheng JK; Chen GD; Ng SC; Peng HY
Pain; 2020 Sep; 161(9):1995-2009. PubMed ID: 32345914
[TBL] [Abstract][Full Text] [Related]
35. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL).
Borkin D; Pollock J; Kempinska K; Purohit T; Li X; Wen B; Zhao T; Miao H; Shukla S; He M; Sun D; Cierpicki T; Grembecka J
J Med Chem; 2016 Feb; 59(3):892-913. PubMed ID: 26744767
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Novel Inhibitors Targeting the Menin-Mixed Lineage Leukemia Interface Using Pharmacophore- and Docking-Based Virtual Screening.
Xu Y; Yue L; Wang Y; Xing J; Chen Z; Shi Z; Liu R; Liu YC; Luo X; Jiang H; Chen K; Luo C; Zheng M
J Chem Inf Model; 2016 Sep; 56(9):1847-55. PubMed ID: 27513308
[TBL] [Abstract][Full Text] [Related]
37. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological inhibition of the mixed lineage leukemia 1-menin interaction aggravates acute kidney injury induced by folic acid and ischemia-reperfusion in mice.
Hou X; Cui B; Qiu A; Liu N; Zhuang S
Am J Physiol Renal Physiol; 2023 Nov; 325(5):F669-F680. PubMed ID: 37733875
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
40. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]